Femasys (FEMY) announces the receipt of the Medicines & Healthcare products Regulatory Agency approvals for the FemaSeed Intratubal Insemination product for female infertility treatment and two diagnostic devices, FemVue for tubal evaluation and FemCerv for cervical cancer detection.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FEMY: